CompletedPhase 3NCT01179217
A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
Studying Sickle cell anemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Emmaus Medical, Inc.
- Principal Investigator
- Yutaka Niihara, MD, MPH, MDChairman and CEO
- Intervention
- L-glutamine(drug)
- Enrollment
- 230 enrolled
- Eligibility
- 5 years · All sexes
- Timeline
- 2010 – 2014
Study locations (30)
- University of South Alabama Medical Center, Mobile, Alabama, United States
- Phoenix Children's Hospital Center for Cancer and Blood Disorders, Phoenix, Arizona, United States
- Kaiser Permanente, Inglewood, California, United States
- Children's Hospital & Research Center at Oakland, Oakland, California, United States
- Children's Hospital of Orange County, Orange, California, United States
- Harbor-UCLA Medical Center, Torrance, California, United States
- University of Denver School of Medicine Sickle Cell Treatment & Research Center, Aurora, Colorado, United States
- Howard University Hospital & Howard University, Washington D.C., District of Columbia, United States
- University of Florida, Gainesville, Florida, United States
- All Children's Hospital, St. Petersburg, Florida, United States
- Children's Healthcare of Atlanta at Egleston/Emory University, Atlanta, Georgia, United States
- University of Illinois at Chicago, Chicago, Illinois, United States
- University of Louisville School of Medicine, Louisville, Kentucky, United States
- Sickle Cell Center of S. Louisiana, Tulane University School of Medicine, New Orleans, Louisiana, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01179217 on ClinicalTrials.govOther trials for Sickle cell anemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07369024Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young AdultsMohsen Saidinejad
- RECRUITINGNCT07373639A Long-term Follow-up Study in Patients Who Received BEAM-101Beam Therapeutics Inc.
- RECRUITINGNANCT07402811Mindfulness-Based Intervention for Pain and Sleep in Adolescents and Young Adults With Sickle Cell DiseaseUniversity of Illinois at Chicago
- RECRUITINGPHASE1NCT06647979Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-HemoglobinopathiesDaniel Bauer
- RECRUITINGNANCT06555939Promoting Resilience Among Adolescents and Young Adults With Sickle Cell DiseaseBoston Children's Hospital
- RECRUITINGPHASE3NCT06975865The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell DiseaseSanofi
- RECRUITINGNCT06944067Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell DiseaseNational Human Genome Research Institute (NHGRI)
- RECRUITINGNCT06923111PASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease [PRECISE PASS]Nova Laboratories Limited